{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:20:46Z","timestamp":1747207246285,"version":"3.40.5"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>The dynamism in the regulatory frameworks concerning the consumption\nof cannabinoids has placed their effects on cognitive and psychomotor skills at the center of\nthe scientific debate. In consideration of the potential repercussions on public safety, particular\nattention has been focused on the impairment of driving skills, opening up the need to specifically\nregulate driving under the effects of cannabinoids.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Pharmacokinetics:<\/jats:title>\n<jats:p>Both native cannabinoids and metabolites show a long positivity at low concentrations\nin the biological fluids, especially in the case of chronic consumption. Qualitative positivity\nto cannabinoids does not itself prove the presence of detrimental effects, which require the\npresence of active substances at relevant concentrations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Driving Skill Impairment:<\/jats:title>\n<jats:p>Multiple studies highlight a tetrahydrocannabinol (THC) concentration-\nbased alteration of driving skills mainly affecting automatisms, whereas skills subjected to\ncognitive control are preserved up to higher dosages. The evidence relating to associations with\nother substances, chronic consumption and other cannabinoids, on the other hand, is still burdened\nby a high degree of uncertainty.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Regulation Policies:<\/jats:title>\n<jats:p>Different models can be adopted in the regulation of driving under the effects\nof cannabinoids: sanctions can be applied in case of qualitative positivity, cannabinoids concentration\nabove a defined threshold, or in presence of a demonstrated state of cognitive alteration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>\"Per se limit\" with a quantitative THC cut-off between 3.5 and 5 ng\/ml can currently\nbe considered the most balanced choice. Finally, the analysis carried out allowed to identify pitfalls\nin both scientific and legislative fields for the improvement of safety policies<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201023666220616160459","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:37:39Z","timestamp":1655458659000},"page":"719-727","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cannabis and Driving: Developing Guidelines for Safety Policies"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-6193","authenticated-orcid":true,"given":"Federico","family":"Manetti","sequence":"first","affiliation":[{"name":"Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8095-1695","authenticated-orcid":true,"given":"Silvio","family":"Chericoni","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2353-5724","authenticated-orcid":true,"given":"Anna","family":"Marrocco","sequence":"additional","affiliation":[{"name":"Department of Law, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-3090","authenticated-orcid":true,"given":"Matteo","family":"Scopetti","sequence":"additional","affiliation":[{"name":"Department of Medical Surgical Sciences and Translational\nMedicine, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-7926","authenticated-orcid":true,"given":"Martina","family":"Padovano","sequence":"additional","affiliation":[{"name":"Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3719","authenticated-orcid":true,"given":"Alessandro","family":"Santurro","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, University of\nSalerno, Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-7965","authenticated-orcid":true,"given":"Paola","family":"Frati","sequence":"additional","affiliation":[{"name":"Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-9077","authenticated-orcid":true,"given":"Mario","family":"Gabbrielli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neuroscience - Section of Legal Medicine, University of\nSiena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1686-3236","authenticated-orcid":true,"given":"Vittorio","family":"Fineschi","sequence":"additional","affiliation":[{"name":"Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"journal-title":"EMCDDA European Drug Report 2017: Trends and Developments","year":"2017","key":"ref=1","unstructured":"EMCDDA European Drug Report 2017: Trends and Developments Available from:  (Accessed on May 27, 2022)2017"},{"year":"2018","key":"ref=2","unstructured":"EMCDDA. Statistical Bulletin 2018. Available from:  (Accessed on May 27, 2022).2018"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ypmed.2017.07.008","volume":"104","author":"Carliner H.","year":"2017","unstructured":"Carliner H.; Brown Q.L.; Sarvet A.L.; Hasin D.S.; Cannabis use, attitudes, and legal status in the U.S.: A review. Prev Med 2017,104,13-23","journal-title":"Prev Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1360-0443.2011.03561.x","volume":"107","author":"Caulkins J.P.","year":"2012","unstructured":"Caulkins J.P.; Kilmer B.; MacCoun R.J.; Pacula R.L.; Reuter P.; Design considerations for legalizing cannabis: Lessons inspired by analysis of California\u2019s Proposition 19. Addiction 2012,107(5),865-871","journal-title":"Addiction"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/wps.20743","volume":"19","author":"van Ours J.C.","year":"2020","unstructured":"van Ours J.C.; Legalizing recreational cannabis use: A promising journey into the unknown. World Psychiatry 2020,19(2),196-197","journal-title":"World Psychiatry"},{"key":"ref=6","first-page":"1011","volume":"89","author":"Carcieri M.","year":"2012","unstructured":"Carcieri M.; On the medicinal-recreational distinction in cannabis law. Denver Univ Law Rev 2012,89(4),1011-1016","journal-title":"Denver Univ Law Rev"},{"journal-title":"United Nations High Commissioner for Human Rights - Human Rights Council Study on the impact of the world drug problem on the enjoyment of human rights Available from:","key":"ref=7","unstructured":"United Nations High Commissioner for Human Rights - Human Rights Council Study on the impact of the world drug problem on the enjoyment of human rights Available from:   (Accessed on May 27, 2022)"},{"journal-title":"Geneva: World Health Organization The health and social effects of nonmedical cannabis use Available from","author":"Hall W.D.","key":"ref=8","unstructured":"Hall W.D.; Renstr\u00f6m M.; Poznyak V.;  Geneva: World Health Organization The health and social effects of nonmedical cannabis use Available from  (Accessed on May 27, 2022)."},{"journal-title":"EMCDDA Cannabis and driving: Questions and answers for policymaking Available from:","key":"ref=9","unstructured":"EMCDDA Cannabis and driving: Questions and answers for policymaking Available from:  (Accessed May 27, 2022)."},{"journal-title":"EMCDDA Driving Under the Influence of Drugs, Alcohol and   Medicines in Europe \u2014 findings from the DRUID project Available from:","key":"ref=10","unstructured":"EMCDDA Driving Under the Influence of Drugs, Alcohol and   Medicines in Europe \u2014 findings from the DRUID project Available from:  https:\/\/www.emcdda.europa.eu\/publications\/thematic-papers\/druid_en (Accessed on May 27, 2022)."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dar.12651","volume":"37","author":"Hall W.","year":"2018","unstructured":"Hall W.; How should we respond to cannabis-impaired driving? Drug Alcohol Rev 2018,37(1),3-5","journal-title":"Drug Alcohol Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"Grotenhermen F.","year":"2003","unstructured":"Grotenhermen F.; Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003,42(4),327-360","journal-title":"Clin Pharmacokinet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/BF02085029","volume":"37","author":"Agurell S.","year":"1981","unstructured":"Agurell S.; Carlsson S.; Lindgren J.E.; Ohlsson A.; Gillespie H.; Hollister L.; Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981,37(10),1090-1092","journal-title":"Experientia"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.yebeh.2016.11.016","volume":"70","author":"Gaston T.E.","year":"2017","unstructured":"Gaston T.E.; Friedman D.;  Pharmacology of cannabinoids in the treatment of epilepsy Epilepsy Behav 2017,70(Pt B),313-3","journal-title":"Pharmacology of cannabinoids in the treatment of epilepsy Epilepsy Behav"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/jat\/31.5.288","volume":"31","author":"Kauert G.F.","year":"2007","unstructured":"Kauert G.F.; Ramaekers J.G.; Schneider E.; Moeller M.R.; Toennes S.W.; Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 2007,31(5),288-293","journal-title":"J Anal Toxicol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15A","DOI":"10.1155\/2005\/242516","volume":"10","author":"McGilveray I.J.","year":"2005","unstructured":"McGilveray I.J.; Pharmacokinetics of cannabinoids. Pain Res Manag 2005,10(Suppl. A),15A-22A","journal-title":"Pain Res Manag"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/03602532.2015.1137307","volume":"48","author":"Dinis-Oliveira R.J.","year":"2016","unstructured":"Dinis-Oliveira R.J.; Metabolomics of \u03949-tetrahydrocannabinol: Implications in toxicity. Drug Metab Rev 2016,48(1),80-87","journal-title":"Drug Metab Rev"},{"key":"ref=18","first-page":"35","volume":"215","author":"Hunt C.A.","year":"1980","unstructured":"Hunt C.A.; Jones R.T.; Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980,215(1),35-44","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"Devinsky O.","year":"2014","unstructured":"Devinsky O.; Cilio M.R.; Cross H.; Fernandez-Ruiz J.; French J.; Hill C.; Katz R.; Di Marzo V.; Jutras-Aswad D.; Notcutt W.G.; Martinez-Orgado J.; Robson P.J.; Rohrback B.G.; Thiele E.; Whalley B.; Friedman D.; Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014,55(6),791-802","journal-title":"Epilepsia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/jcph.1387","volume":"59","author":"White C.M.","year":"2019","unstructured":"White C.M.; A review of human studies assessing cannabidiol\u2019s (CBD) therapeutic actions and potential. J Clin Pharmacol 2019,59(7),923-934","journal-title":"J Clin Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/jat\/bkv082","volume":"39","author":"Lee D.","year":"2015","unstructured":"Lee D.; Bergamaschi M.M.; Milman G.; Barnes A.J.; Queiroz R.H.; Vandrey R.; Huestis M.A.; Plasma cannabinoid pharmacokinetics after controlled smoking and ad libitum cannabis smoking in chronic frequent users. J Anal Toxicol 2015,39(8),580-587","journal-title":"J Anal Toxicol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40262-017-0599-0","volume":"57","author":"Martin J.H.","year":"2018","unstructured":"Martin J.H.; Schneider J.; Lucas C.J.; Galettis P.; Exogenous cannabinoid efficacy: merely a pharmacokinetic interaction? Clin Pharmacokinet 2018,57(5),539-545","journal-title":"Clin Pharmacokinet"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/clpt.1985.226","volume":"38","author":"Ellis G.M.","year":"1985","unstructured":"Ellis G.M.; Mann M.A.; Judson B.A.; Schramm N.T.; Tashchian A.; Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985,38(5),572-578","journal-title":"Clin Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","volume":"62","author":"Newmeyer M.N.","year":"2016","unstructured":"Newmeyer M.N.; Swortwood M.J.; Barnes A.J.; Abulseoud O.A.; Scheidweiler K.B.; Huestis M.A.; Free and glucuronide whole blood cannabinoids\u2019 pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem 2016,62(12),1579-1592","journal-title":"Clin Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s00414-020-02387-w","volume":"134","author":"Hassenberg C.","year":"2020","unstructured":"Hassenberg C.; Clausen F.; Hoffmann G.; Studer A.; Sch\u00fcrenkamp J.; Investigation of phase II metabolism of 11-hydroxy-\u0394-9-tetrahydrocannabinol and metabolite verification by chemical synthesis of 11-hydroxy-\u0394-9-tetrahydrocannabinol-glucuronide. Int J Legal Med 2020,134(6),2105-2119","journal-title":"Int J Legal Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1373\/clinchem.2012.195503","volume":"59","author":"Bergamaschi M.M.","year":"2013","unstructured":"Bergamaschi M.M.; Karschner E.L.; Goodwin R.S.; Scheidweiler K.B.; Hirvonen J.; Queiroz R.H.; Huestis M.A.; Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers\u2019 blood on per se drugged driving laws. Clin Chem 2013,59(3),519-526","journal-title":"Clin Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1111\/j.1360-0443.2009.02705.x","volume":"104","author":"Karschner E.L.","year":"2009","unstructured":"Karschner E.L.; Schwilke E.W.; Lowe R.H.; Darwin W.D.; Pope H.G.; Herning R.; Cadet J.L.; Huestis M.A.; Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009,104(12),2041-2048","journal-title":"Addiction"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"Lucas C.J.","year":"2018","unstructured":"Lucas C.J.; Galettis P.; Schneider J.; The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018,84(11),2477-2482","journal-title":"Br J Clin Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/bms.1200130206","volume":"13","author":"Ohlsson A.","year":"1986","unstructured":"Ohlsson A.; Lindgren J.E.; Andersson S.; Agurell S.; Gillespie H.; Hollister L.E.; Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 1986,13(2),77-83","journal-title":"Biomed Environ Mass Spectrom"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"Millar S.A.","year":"2018","unstructured":"Millar S.A.; Stone N.L.; Yates A.S.; O\u2019Sullivan S.E.; A Systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 2018,9(9),1365","journal-title":"Front Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"Consroe P.","year":"1991","unstructured":"Consroe P.; Laguna J.; Allender J.; Snider S.; Stern L.; Sandyk R.; Kennedy K.; Schram K.; Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 1991,40(3),701-708","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.addbeh.2012.09.001","volume":"38","author":"Boden M.T.","year":"2013","unstructured":"Boden M.T.; Gross J.J.; Babson K.A.; Bonn-Miller M.O.; The interactive effects of emotional clarity and cognitive reappraisal on problematic cannabis use among medical cannabis users. Addict Behav 2013,38(3),1663-1668","journal-title":"Addict Behav"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125312457586","volume":"2","author":"Atakan Z.","year":"2012","unstructured":"Atakan Z.; Cannabis, a complex plant: Different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012,2(6),241-254","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.clinthera.2018.03.013","volume":"40","author":"De Aquino J.P.","year":"2018","unstructured":"De Aquino J.P.; Sherif M.; Radhakrishnan R.; Cahill J.D.; Ranganathan M.; D\u2019Souza D.C.; The psychiatric consequences of cannabinoids. Clin Ther 2018,40(9),1448-1456","journal-title":"Clin Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/j.1360-0443.2007.02009.x","volume":"102","author":"Grotenhermen F.","year":"2007","unstructured":"Grotenhermen F.; Leson G.; Berghaus G.; Drummer O.H.; Kr\u00fcger H.P.; Longo M.; Moskowitz H.; Perrine B.; Ramaekers J.G.; Smiley A.; Tunbridge R.; Developing limits for driving under cannabis. Addiction 2007,102(12),1910-1917","journal-title":"Addiction"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpba.2017.12.059","volume":"151","author":"Del Balzo G.","year":"2018","unstructured":"Del Balzo G.; Gottardo R.; Mengozzi S.; Dorizzi R.M.; Bortolotti F.; Appolonova S.; Tagliaro F.; \u201cPositive\u201d urine testing for cannabis is associated with increased risk of traffic crashes. J Pharm Biomed Anal 2018,151(151),71-74","journal-title":"J Pharm Biomed Anal"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.drugalcdep.2011.10.023","volume":"123","author":"Johnson M.B.","year":"2012","unstructured":"Johnson M.B.; Kelley-Baker T.; Voas R.B.; Lacey J.H.; The prevalence of cannabis-involved driving in California. Drug Alcohol Depend 2012,123(1-3),105-109","journal-title":"Drug Alcohol Depend"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugalcdep.2015.02.024","volume":"150","author":"Pollini R.A.","year":"2015","unstructured":"Pollini R.A.; Romano E.; Johnson M.B.; Lacey J.H.; The impact of marijuana decriminalization on California drivers. Drug Alcohol Depend 2015,150,135-140","journal-title":"Drug Alcohol Depend"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15389588.2020.1847281","volume":"22","author":"Beirness D.J.","year":"2021","unstructured":"Beirness D.J.; Gu K.W.; Lowe N.J.; Woodall K.L.; Desrosiers N.A.; Cahill B.; Porath A.J.; Peaire A.; Cannabis, alcohol and other drug findings in fatally injured drivers in Ontario. Traffic Inj Prev 2021,22(1),1-6","journal-title":"Traffic Inj Prev"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1136\/bmj.e536","volume":"344","author":"Asbridge M.","year":"2012","unstructured":"Asbridge M.; Hayden J.A.; Cartwright J.L.;  Acute cannabis consumption\nand motor vehicle collision risk: Systematic review of  observational studies and meta-analysis. BMJ 2012,344(feb09 2),e536","journal-title":"BMJ"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0001-4575(02)00153-7","volume":"36","author":"Drummer O.H.","year":"2004","unstructured":"Drummer O.H.; Gerostamoulos J.; Batziris H.; Chu M.; Caplehorn J.; Robertson M.D.; Swann P.; The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004,36(2),239-248","journal-title":"Accid Anal Prev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/bmj.38648.617986.1F","volume":"331","author":"Laumon B.","year":"2005","unstructured":"Laumon B.; Gadegbeku B.; Martin J.L.; Biecheler M.B.; Group S.A.M.; Cannabis intoxication and fatal road crashes in France: Population based case-control study. BMJ 2005,331(7529),1371","journal-title":"BMJ"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","volume":"79","author":"Broyd S.J.","year":"2016","unstructured":"Broyd S.J.; van Hell H.H.; Beale C.; Y\u00fccel M.; Solowij N.; Acute and chronic effects of cannabinoids on human cognition-A systematic review. Biol Psychiatry 2016,79(7),557-567","journal-title":"Biol Psychiatry"},{"key":"ref=44","first-page":"S31","volume":"32","author":"Solowij N.","year":"2010","unstructured":"Solowij N.; Pesa N.;  [Cognitive abnormalities and cannabis use Rev Bras Psiquiatr 2010,32(Suppl. 1),S31-S40","journal-title":"[Cognitive abnormalities and cannabis use Rev Bras Psiquiatr"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.tics.2006.02.008","volume":"10","author":"Fletcher P.C.","year":"2006","unstructured":"Fletcher P.C.; Honey G.D.; Schizophrenia, ketamine and cannabis: Evidence of overlapping memory deficits. Trends Cogn Sci 2006,10(4),167-174","journal-title":"Trends Cogn Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00213-006-0508-y","volume":"188","author":"Ranganathan M.","year":"2006","unstructured":"Ranganathan M.; D\u2019Souza D.C.; The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology (Berl) 2006,188(4),425-444","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","volume":"29","author":"D\u2019Souza D.C.","year":"2004","unstructured":"D\u2019Souza D.C.; Perry E.; MacDougall L.; Ammerman Y.; Cooper T.; Wu Y.T.; Braley G.; Gueorguieva R.; Krystal J.H.; The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004,29(8),1558-1572","journal-title":"Neuropsychopharmacology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00213-007-1042-2","volume":"198","author":"D\u2019Souza D.C.","year":"2008","unstructured":"D\u2019Souza D.C.; Braley G.; Blaise R.; Vendetti M.; Oliver S.; Pittman B.; Ranganathan M.; Bhakta S.; Zimolo Z.; Cooper T.; Perry E.; Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2008,198(4),587-603","journal-title":"Psychopharmacology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00213-008-1440-0","volume":"204","author":"Hunault C.C.","year":"2009","unstructured":"Hunault C.C.; Mensinga T.T.; B\u00f6cker K.B.; Schipper C.M.; Kruidenier M.; Leenders M.E.; de Vries I.; Meulenbelt J.; Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology 2009,204(1),85-94","journal-title":"Psychopharmacology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jsat.2014.07.014","volume":"48","author":"Kollins S.H.","year":"2015","unstructured":"Kollins S.H.; Schoenfelder E.N.; English J.S.; Holdaway A.; Van Voorhees E.; O\u2019Brien B.R.; Dew R.; Chrisman A.K.; An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults. J Subst Abuse Treat 2015,48(1),96-103","journal-title":"J Subst Abuse Treat"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"657371","DOI":"10.3389\/fpsyt.2021.657371","volume":"12","author":"Morie K.P.","year":"2021","unstructured":"Morie K.P.; Potenza M.N.; A mini-review of relationships between cannabis use and neural foundations of reward processing, inhibitory control and working memory. Front Psychiatry 2021,12,657371","journal-title":"Front Psychiatry"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/adb.12111","volume":"19","author":"Cousijn J.","year":"2014","unstructured":"Cousijn J.; Vingerhoets W.A.; Koenders L.; de Haan L.; van den Brink W.; Wiers R.W.; Goudriaan A.E.; Relationship between working-memory network function and substance use: A 3-year longitudinal fMRI study in heavy cannabis users and controls. Addict Biol 2014,19(2),282-293","journal-title":"Addict Biol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1002\/hbm.22342","volume":"35","author":"Cousijn J.","year":"2014","unstructured":"Cousijn J.; Wiers R.W.; Ridderinkhof K.R.; van den Brink W.; Veltman D.J.; Goudriaan A.E.; Effect of baseline cannabis use and working-memory network function on changes in cannabis use in heavy cannabis users: A prospective FMRI study. Hum Brain Mapp 2014,35(5),2470-2482","journal-title":"Hum Brain Mapp"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0269881107084000","volume":"22","author":"Fisk J.E.","year":"2008","unstructured":"Fisk J.E.; Montgomery C.; Real-world memory and executive processes in cannabis users and non-users. J Psychopharmacol 2008,22(7),727-736","journal-title":"J Psychopharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1017\/S0033291709005522","volume":"39","author":"Morrison P.D.","year":"2009","unstructured":"Morrison P.D.; Zois V.; McKeown D.A.; Lee T.D.; Holt D.W.; Powell J.F.; Kapur S.; Murray R.M.; The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009,39(10),1607-1616","journal-title":"Psychol Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.drugalcdep.2006.03.015","volume":"85","author":"Ramaekers J.G.","year":"2006","unstructured":"Ramaekers J.G.; Moeller M.R.; van Ruitenbeek P.; Theunissen E.L.; Schneider E.; Kauert G.; Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend 2006,85(2),114-122","journal-title":"Drug Alcohol Depend"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1038\/sj.npp.1301068","volume":"31","author":"Ramaekers J.G.","year":"2006","unstructured":"Ramaekers J.G.; Kauert G.; van Ruitenbeek P.; Theunissen E.L.; Schneider E.; Moeller M.R.; High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 2006,31(10),2296-2303","journal-title":"Neuropsychopharmacology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/0269881108092393","volume":"23","author":"Ramaekers J.G.","year":"2009","unstructured":"Ramaekers J.G.; Kauert G.; Theunissen E.L.; Toennes S.W.; Moeller M.R.; Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009,23(3),266-277","journal-title":"J Psychopharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/1099-1077(200010)15:7<551:AID-HUP236>3.0.CO;2-P","volume":"15","author":"Ramaekers J.G.","year":"2000","unstructured":"Ramaekers J.G.; Robbe H.W.J.; O\u2019Hanlon J.F.; Marijuana, alcohol and actual driving performance. Hum Psychopharmacol 2000,15(7),551-558","journal-title":"Hum Psychopharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.3390\/ijerph17239033","volume":"17","author":"Ortiz-Peregrina S.","year":"2020","unstructured":"Ortiz-Peregrina S.; Ortiz C.; Castro-Torres J.J.; Jim\u00e9nez J.R.; Anera R.G.; Effects of smoking cannabis on visual function and driving performance. A driving-simulator based study. Int J Environ Res Public Health 2020,17(23),9033","journal-title":"Int J Environ Res Public Health"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.drugalcdep.2003.10.008","volume":"73","author":"Ramaekers J.G.","year":"2004","unstructured":"Ramaekers J.G.; Berghaus G.; van Laar M.; Drummer O.H.; Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend 2004,73(2),109-119","journal-title":"Drug Alcohol Depend"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/10550490902786934","volume":"18","author":"Sewell R.A.","year":"2009","unstructured":"Sewell R.A.; Poling J.; Sofuoglu M.; The effect of cannabis compared with alcohol on driving. Am J Addict 2009,18(3),185-193","journal-title":"Am J Addict"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/fcp.12382","volume":"32","author":"Micallef J.","year":"2018","unstructured":"Micallef J.; Dupouey J.; Jouve E.; Truillet R.; Lacarelle B.; Taillard J.; Daurat A.; Authi\u00e9 C.; Blin O.; Rascol O.; Philip P.; Mestre D.; Cannabis smoking impairs driving performance on the simulator and real driving: A randomized, double-blind, placebo-controlled, crossover trial. Fundam Clin Pharmacol 2018,32(5),558-570","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugalcdep.2015.06.015","volume":"154","author":"Hartman R.L.","year":"2015","unstructured":"Hartman R.L.; Brown T.L.; Milavetz G.; Spurgin A.; Pierce R.S.; Gorelick D.A.; Gaffney G.; Huestis M.A.; Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend 2015,154,25-37","journal-title":"Drug Alcohol Depend"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00213-021-05773-3","volume":"239","author":"Fares A.","year":"2021","unstructured":"Fares A.; Wickens C.M.; Mann R.E.; Di Ciano P.; Wright M.; Matheson J.; Hasan O.S.M.; Rehm J.; George T.P.; Samokhvalov A.V.; Shuper P.A.; Huestis M.A.; Stoduto G.; Brown T.; Stefan C.; Rubin-Kahana D.S.; Le Foll B.; Brands B.; Combined effect of alcohol and cannabis on simulated driving. Psychopharmacology 2021,239(5),1263-1277","journal-title":"Psychopharmacology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1080\/15389588.2021.1933459","volume":"22","author":"Burt T.S.","year":"2021","unstructured":"Burt T.S.; Brown T.L.; Schmitt R.; McGehee D.; Milavetz G.; Gaffney G.R.; Berka C.; Perceived effects of cannabis and changes in driving performance under the influence of cannabis. Traffic Inj Prev 2021,22(sup1),S8-S13","journal-title":"Traffic Inj Prev"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1360-0443.2005.01100.x","volume":"100","author":"Blows S.","year":"2005","unstructured":"Blows S.; Ivers R.Q.; Connor J.; Ameratunga S.; Woodward M.; Norton R.; Marijuana use and car crash injury. Addiction 2005,100(5),605-611","journal-title":"Addiction"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.forsciint.2016.09.007","volume":"268","author":"Bondallaz P.","year":"2016","unstructured":"Bondallaz P.; Favrat B.; Chtioui H.; Fornari E.; Maeder P.; Giroud C.; Cannabis and its effects on driving skills. Forensic Sci Int 2016,268,92-102","journal-title":"Forensic Sci Int"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000505","author":"Wickens C.M.","year":"2021","unstructured":"Wickens C.M.; Mann R.E.; Brands B.; Stoduto G.; Matheson J.; Sayer G.; Burston J.; Pan J.F.; Di Ciano P.; George T.P.; Rehm J.; Kenney C.; Soule D.; Huestis M.A.; Le Foll B.; Influence of personality on acute smoked cannabis effects on simulated driving. Exp Clin Psychopharmacol 2021","journal-title":"Exp Clin Psychopharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1037\/neu0000281","volume":"30","author":"Schuster R.M.","year":"2016","unstructured":"Schuster R.M.; Hoeppner S.S.; Evins A.E.; Gilman J.M.; Early onset marijuana use is associated with learning inefficiencies. Neuropsychology 2016,30(4),405-415","journal-title":"Neuropsychology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1037\/a0026269","volume":"26","author":"Gruber S.A.","year":"2012","unstructured":"Gruber S.A.; Sagar K.A.; Dahlgren M.K.; Racine M.; Lukas S.E.; Age of onset of marijuana use and executive function. Psychol Addict Behav 2012,26(3),496-506","journal-title":"Psychol Addict Behav"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"107771","DOI":"10.1016\/j.drugalcdep.2019.107771","volume":"208","author":"Dahlgren M.K.","year":"2020","unstructured":"Dahlgren M.K.; Sagar K.A.; Smith R.T.; Lambros A.M.; Kuppe M.K.; Gruber S.A.; Recreational cannabis use impairs driving performance in the absence of acute intoxication. Drug Alcohol Depend 2020,208,107771","journal-title":"Drug Alcohol Depend"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugalcdep.2010.11.024","volume":"116","author":"Griffith-Lendering M.F.","year":"2011","unstructured":"Griffith-Lendering M.F.; Huijbregts S.C.; Mooijaart A.; Vollebergh W.A.; Swaab H.; Cannabis use and development of externalizing and internalizing behaviour problems in early adolescence: A TRAILS study. Drug Alcohol Depend 2011,116(1-3),11-17","journal-title":"Drug Alcohol Depend"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2006.12.011","volume":"88","author":"Fergusson D.M.","year":"2007","unstructured":"Fergusson D.M.; Horwood L.J.; Ridder E.M.; Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: Results of a 25-year longitudinal study. Drug Alcohol Depend 2007,88(Suppl. 1),S14-S26","journal-title":"Drug Alcohol Depend"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1389201018666170207124835","volume":"18","author":"La Russa R.","year":"2017","unstructured":"La Russa R.; Fineschi V.; Di Sanzo M.; Gatto V.; Santurro A.; Martini G.; Scopetti M.; Frati P.; Personalized medicine and adverse drug reactions: The experience of an Italian teaching hospital. Curr Pharm Biotechnol 2017,18(3),274-281","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e2749","DOI":"10.1002\/hup.2749","volume":"35","author":"McCartney D.","year":"2020","unstructured":"McCartney D.; Benson M.J.; Suraev A.S.; Irwin C.; Arkell T.R.; Grunstein R.R.; Hoyos C.M.; McGregor I.S.; The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol. Hum Psychopharmacol 2020,35(5),e2749","journal-title":"Hum Psychopharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1001\/jama.2020.21218","volume":"324","author":"Arkell T.R.","year":"2020","unstructured":"Arkell T.R.; Vinckenbosch F.; Kevin R.C.; Theunissen E.L.; McGregor I.S.; Ramaekers J.G.; Effect of cannabidiol and \u03949-tetrahydrocannabinol on driving performance: A randomized clinical trial. JAMA 2020,324(21),2177-2186","journal-title":"JAMA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2147\/IJGM.S275049","volume":"13","author":"Gottschling S.","year":"2020","unstructured":"Gottschling S.; Ayonrinde O.; Bhaskar A.; Blockman M.; D\u2019Agnone O.; Schecter D.; Su\u00e1rez Rodr\u00edguez L.D.; Yafai S.; Cyr C.; Safety considerations in cannabinoid-based medicine. Int J Gen Med 2020,13,1317-1333","journal-title":"Int J Gen Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"Laprairie R.B.","year":"2015","unstructured":"Laprairie R.B.; Bagher A.M.; Kelly M.E.; Denovan-Wright E.M.; Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015,172(20),4790-4805","journal-title":"Br J Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1111\/j.1476-5381.2011.01621.x","volume":"165","author":"Rock E.M.","year":"2012","unstructured":"Rock E.M.; Bolognini D.; Limebeer C.L.; Cascio M.G.; Anavi-Goffer S.; Fletcher P.J.; Mechoulam R.; Pertwee R.G.; Parker L.A.; Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012,165(8),2620-2634","journal-title":"Br J Pharmacol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/35003583","volume":"404","author":"Baker D.","year":"2000","unstructured":"Baker D.; Pryce G.; Croxford J.L.; Brown P.; Pertwee R.G.; Huffman J.W.; Layward L.; Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000,404(6773),84-87","journal-title":"Nature"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"McGuire P.","year":"2018","unstructured":"McGuire P.; Robson P.; Cubala W.J.; Vasile D.; Morrison P.D.; Barron R.; Taylor A.; Wright S.; Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry 2018,175(3),225-231","journal-title":"Am J Psychiatry"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"Boggs D.L.","year":"2018","unstructured":"Boggs D.L.; Surti T.; Gupta A.; Gupta S.; Niciu M.; Pittman B.; Schnakenberg Martin A.M.; Thurnauer H.; Davies A.; D\u2019Souza D.C.; Ranganathan M.; The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 2018,235(7),1923-1932","journal-title":"Psychopharmacology"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"Leweke F.M.","year":"2012","unstructured":"Leweke F.M.; Piomelli D.; Pahlisch F.; Muhl D.; Gerth C.W.; Hoyer C.; Klosterk\u00f6tter J.; Hellmich M.; Koethe D.; Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012,2(3),e94","journal-title":"Transl Psychiatry"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"Englund A.","year":"2013","unstructured":"Englund A.; Morrison P.D.; Nottage J.; Hague D.; Kane F.; Bonaccorso S.; Stone J.M.; Reichenberg A.; Brenneisen R.; Holt D.; Feilding A.; Walker L.; Murray R.M.; Kapur S.; Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013,27(1),19-27","journal-title":"J Psychopharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","volume":"197","author":"Morgan C.J.","year":"2010","unstructured":"Morgan C.J.; Schafer G.; Freeman T.P.; Curran H.V.; Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study: Naturalistic study. Br J Psychiatry 2010,197(4),285-290","journal-title":"Br J Psychiatry"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1017\/S0033291711001322","volume":"42","author":"Morgan C.J.","year":"2012","unstructured":"Morgan C.J.; Gardener C.; Schafer G.; Swan S.; Demarchi C.; Freeman T.P.; Warrington P.; Rupasinghe I.; Ramoutar A.; Tan N.; Wingham G.; Lewis S.; Curran H.V.; Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2012,42(2),391-400","journal-title":"Psychol Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s00213-019-05246-8","volume":"236","author":"Arkell T.R.","year":"2019","unstructured":"Arkell T.R.; Lintzeris N.; Kevin R.C.; Ramaekers J.G.; Vandrey R.; Irwin C.; Haber P.S.; McGregor I.S.; Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology 2019,236(9),2713-2724","journal-title":"Psychopharmacology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.forsciint.2016.11.017","volume":"269","author":"Berthet A.","year":"2016","unstructured":"Berthet A.; De Cesare M.; Favrat B.; Sporkert F.; Augsburger M.; Thomas A.; Giroud C.; A systematic review of passive exposure to cannabis. Forensic Sci Int 2016,269,97-112","journal-title":"Forensic Sci Int"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jamapsychiatry.2017.0723","volume":"74","author":"Compton W.M.","year":"2017","unstructured":"Compton W.M.; Volkow N.D.; Lopez M.F.; Medical marijuana laws and cannabis use: Intersections of health and policy. JAMA Psychiatry 2017,74(6),559-560","journal-title":"JAMA Psychiatry"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00213-012-2787-9","volume":"224","author":"Downey L.A.","year":"2012","unstructured":"Downey L.A.; King R.; Papafotiou K.; Swann P.; Ogden E.; Boorman M.; Stough C.; Detecting impairment associated with cannabis with and without alcohol on the Standardized Field Sobriety Tests. Psychopharmacology 2012,224(4),581-589","journal-title":"Psychopharmacology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/15389588.2018.1562178","volume":"20","author":"Porath A.J.","year":"2019","unstructured":"Porath A.J.; Beirness D.J.; Predicting categories of drugs used by suspected drug-impaired drivers using the drug evaluation and classification program tests. Traffic Inj Prev 2019,20(3),255-263","journal-title":"Traffic Inj Prev"},{"key":"ref=93","unstructured":"EMCDDA. A cannabis reader: Global issues and local experiences: Volume 1Available from:   (Accessed on May 27, 2022)."},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2125.2008.03329.x","volume":"67","author":"Zuurman L.","year":"2009","unstructured":"Zuurman L.; Ippel A.E.; Moin E.; van Gerven J.M.; Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009,67(1),5-21","journal-title":"Br J Clin Pharmacol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.aap.2016.04.012","volume":"92","author":"Hartman R.L.","year":"2016","unstructured":"Hartman R.L.; Richman J.E.; Hayes C.E.; Huestis M.A.; Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. Accid Anal Prev 2016,92,219-229","journal-title":"Accid Anal Prev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2174\/1389201018666170208125131","volume":"18","author":"Borro M.","year":"2017","unstructured":"Borro M.; Gentile G.; Cipolloni L.; Foldes-Papp Z.; Frati P.; Santurro A.; Lionetto L.; Simmaco M.; Personalised healthcare: The DiMA clinical model. Curr Pharm Biotechnol 2017,18(3),242-252","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2174\/1389201018666170224105600","volume":"18","author":"Di Sanzo M.","year":"2017","unstructured":"Di Sanzo M.; Cipolloni L.; Borro M.; La Russa R.; Santurro A.; Scopetti M.; Simmaco M.; Frati P.; Clinical applications of personalized medicine: A new paradigm and challenge. Curr Pharm Biotechnol 2017,18(3),194-203","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2174\/1389201018666170207141525","volume":"18","author":"Santurro A.","year":"2017","unstructured":"Santurro A.; Vullo A.M.; Borro M.; Gentile G.; La Russa R.; Simmaco M.; Frati P.; Fineschi V.; Personalized medicine applied to forensic sciences: New advances and perspectives for a tailored forensic approach. Curr Pharm Biotechnol 2017,18(3),263-273","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1213\/ANE.0000000000003575","volume":"128","author":"Chow R.M.","year":"2019","unstructured":"Chow R.M.; Marascalchi B.; Abrams W.B.; Peiris N.A.; Odonkor C.A.; Cohen S.P.; Driving under the influence of cannabis: A framework for future policy. Anesth Analg 2019,128(6),1300-1308","journal-title":"Anesth Analg"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00414-020-02309-w","volume":"134","author":"Manetti F.","year":"2020","unstructured":"Manetti F.; Scopetti M.; Santurro A.; Consoloni L.; D\u2019Errico S.; Widespread septic embolization in injection drug use mitro-aortic infective endocarditis as a remote cause of death. Int J Legal Med 2020,134(4),1345-1351","journal-title":"Int J Legal Med"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220616160459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206102\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220616160459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:43:36Z","timestamp":1698659016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206102\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201023666220616160459","relation":{},"ISSN":["1389-2010"],"issn-type":[{"type":"print","value":"1389-2010"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}